GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading

Citi remains noncommittal on GSK shares despite what it describes as a significant clinical breakthrough in hepatitis B treatment. The note suggests the scientific progress is meaningful, but not yet enough to justify a bullish recommendation. The article is primarily analyst commentary and is unlikely to move the broader market.

Analysis

Citi remains noncommittal on GSK shares despite what it describes as a significant clinical breakthrough in hepatitis B treatment. The note suggests the scientific progress is meaningful, but not yet enough to justify a bullish recommendation. The article is primarily analyst commentary and is unlikely to move the broader market.